Research Article
Differential Expression of IFN-γ, IL-10, TLR1, and TLR2 and Their Potential Effects on Downgrading Leprosy Reaction and Erythema Nodosum Leprosum
Table 1
Clinical and epidemiological variables of reactional and reaction-free leprosy patients.
| | I/TT | BT (PB) | BT(MB) | BB | BL | LL | Total of groups | Total | Leprosy reaction | Reaction-free | Leprosy reaction | Reaction-free | Leprosy reaction | Reaction-free | Leprosy reaction | Reaction-free | Leprosy reaction | Reaction-free | Leprosy reaction | Reaction-fee | Leprosy reaction | Reaction-free | | % | ° | % | | % | | % | | % | | % | | % | | % | | % | | % | | % | | % | | % | | % | | % |
| Operational classification | PB | 0 | 0 | 6 | 100 | 0 | 0 | 2 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 47 | 8 | 23.6 | MB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 20 | 4 | 80 | 4 | 80 | 1 | 20 | 3 | 60 | 2 | 40 | 9 | 81.8 | 2 | 18 | 17 | 100 | 9 | 53 | 23 | 67.6 | Leprosy reaction | T1R | | | | | | | | | 1 | 5.9 | | | 4 | 23.5 | | | 2 | 11.8 | | | 0 | 0 | | | 7 | 41.2 | | | 7 | 20.5 | ENL | | | | | | | | | 0 | 0 | | | 0 | 0 | | | 1 | 5.9 | | | 9 | 53 | | | 10 | 58.8 | | | 10 | 29.4 | Period of occurrence of leprosy reaction | Before treatment | | | | | | | | | 1 | 5.9 | | | 3 | 17.6 | | | 1 | 5.9 | | | 0 | 0 | | | 5 | 29.4 | | | 5 | 14.7 | During treatment | | | | | | | | | 0 | 0 | | | 0 | 0 | | | 0 | 0 | | | 0 | 0 | | | 0 | 0 | | | 0 | 0 | After treatment | | | | | | | | | 0 | 0 | | | 1 | 5.9 | | | 2 | 11.8 | | | 9 | 53 | | | 12 | 70.6 | | | 12 | 35.2 | Disability grade | 0 | 0 | 0 | 6 | 100 | 0 | 0 | 2 | 100 | 1 | 20 | 3 | 60 | 1 | 20 | 0 | 0 | 1 | 20 | 2 | 40 | 5 | 46 | 0 | 0 | 8 | 23.5 | 13 | 38.2 | 21 | 61.7 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 20 | 1 | 20 | 1 | 20 | 1 | 20 | 0 | 0 | 3 | 27 | 2 | 18 | 5 | 14.7 | 4 | 11.8 | 9 | 26.4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 40 | 0 | 0 | 1 | 20 | 0 | 0 | 1 | 9 | 0 | 0 | 4 | 11.8 | 0 | 0 | 4 | 11.7 | Sex | Male | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 100 | 1 | 20 | 4 | 80 | 2 | 40 | 1 | 20 | 2 | 40 | 2 | 40 | 5 | 45.5 | 1 | 9.1 | 10 | 58.8 | 10 | 58.8 | 20 | 58.8 | Female | 0 | 0 | 6 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 40 | 0 | 0 | 1 | 20 | 0 | 0 | 4 | 36.3 | 1 | 9.1 | 7 | 41.2 | 7 | 41.2 | 14 | 41.2 | Age group | 18-24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2.9 | 0 | 0.0 | 1 | 2.9 | 25-34 | 0 | 0 | 2 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 20 | 1 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 9.09 | 0 | 0 | 2 | 5.9 | 3 | 8.8 | 5 | 14.7 | 35-44 | 0 | 0 | 3 | 50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 20 | 1 | 20 | 2 | 40 | 0 | 0 | 2 | 19 | 1 | 9 | 5 | 14.7 | 5 | 14.7 | 10 | 29.4 | 45-54 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 50 | 0 | 0 | 1 | 20 | 1 | 20 | 0 | 0 | 0 | 0 | 1 | 20 | 3 | 27.3 | 1 | 9 | 4 | 11.8 | 4 | 11.8 | 8 | 23.6 | 55-64 | 0 | 0 | 1 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 27.3 | 0 | 0 | 3 | 8.8 | 1 | 2.9 | 4 | 11.7 | ≥65 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 50 | 1 | 20 | 2 | 40 | 0 | 0 | 0 | 0 | 1 | 20 | 1 | 20 | 0 | 0 | 0 | 0 | 2 | 5.9 | 4 | 11.8 | 6 | 17.7 | | Total | 0 | 0 | 6 | 35.2 | 0 | 0 | 2 | 11.8 | 1 | 5.9 | 4 | 23.5 | 4 | 23.5 | 1 | 5.9 | 3 | 17.6 | 2 | 11.8 | 9 | 53 | 2 | 11.8 | 17 | 50 | 17 | 50 | 34 | 100 |
|
|
I: indeterminate leprosy; TT: tuberculoid leprosy; BT: borderline tuberculoid; BB: borderline borderline; BL: borderline lepromatous; LL: lepromatous leprosy; PB: paucibacillary; MB: multibacillary;
|